Intrinsic Value of S&P & Nasdaq Contact Us

Clene Inc. CLNN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$50.00
+649.1%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Clene Inc. (CLNN) has a negative trailing P/E of -2.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 3.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -43.13%, forward earnings yield 27.78%. PEG 0.03 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.03); analyst target implies upside (+649.1%).
  • Forward P/E 3.6 — analysts expect a return to profitability with estimated EPS of $1.85 for FY2028.
  • PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -43.13% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 27.78% as earnings recover.
  • Analyst consensus target $50.00 (+649.1% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 36/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
36/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
94/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
MOAT
35/100
→ Income
GROWTH
15/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — CLNN

Valuation Multiples
P/E (TTM)-2.3
Forward P/E3.6
PEG Ratio0.03
Forward PEG0.03
P/B Ratio-3.45
P/S Ratio307.75
EV/EBITDA-3.6
Per Share Data
EPS (TTM)$-2.65
Forward EPS (Est.)$1.85
Book Value / Share$-1.78
Revenue / Share$0.02
FCF / Share$-1.89
Yields & Fair Value
Earnings Yield-43.13%
Forward Earnings Yield27.78%
Dividend Yield0.00%
Analyst Target$50.00 (+649.1%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2017 -254,888.5 0.00 0.00 0.00 -
2018 -2,227.7 -0.20 123.56 0.00 -
2019 -45.0 -0.01 148.89 0.00 -
2020 -32.7 -1.87 1,849.98 3,062.35 -
2021 -25.9 0.61 20.04 349.09 -
2022 -2.2 -0.05 20.14 137.85 -
2023 -0.6 -0.01 2.32 47.58 -
2024 -0.9 0.02 -4.17 107.97 -
2025 -2.2 0.04 -3.29 289.36 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2017 $0.00 $0.00 $-2.39K -
2018 $-0.09 $0.00 $-277.31K -
2019 $-4.69 $0.00 $-16.27M -
2020 $-5.51 $206K $-19.28M -9357.8%
2021 $-3.16 $723K $-9.74M -1347.2%
2022 $-4.69 $473K $-15.28M -3230.2%
2023 $-9.43 $654K $-49.5M -7569.4%
2024 $-5.67 $342K $-39.4M -11520.5%
2025 $-2.65 $200K $-26.17M -13086.5%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-2.06 $-2.15 – $-1.95 $238.4K $158.93K – $317.87K 3
2027 $-1.28 $-1.64 – $-0.92 $37.71M $1.69M – $73.72M 3
2028 $1.85 $-0.87 – $7.42 $165.79M $13.96M – $317.63M 6
2029 $5.53 $-1.05 – $12.12 $300.15M $25.28M – $575.03M 4
2030 $8.73 $-1.66 – $19.12 $457.66M $38.54M – $876.78M 2
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message